Tune in as Joe Magyer and Gaby Lapera talk about leverage, return on assets, and whether or not to buy Australian banks. 

We look at recently public Nutanix, explain what they do and break down their business.

Taser International just lost a big client, but things aren’t always what they seem.

The approval of Medtronic's artificial pancreas system ushers in a new era for type 1 diabetes treatment. Plus, a new study includes some surprising revelations regarding medical marijuana.

From the shoes on your feet to your daily dose of caffeine, many consumer and retail companies are giving people the opportunity to add a flair of customization to the products they buy, generating growth and brand loyalty in the process.